April 15, 2015
Bone Up on Bone Health

While bone may seem like a static tissue, it is actually very dynamic, undergoing the constant process of remodeling, including both the breaking down (resorption) and rebuilding (deposition) of tissue. Peak bone mass is reached around age 30, after which time it steadily declines. The rate at which it declines is determined by the balance between the activity of osteoclasts, the cells that break down bone, and osteoblasts, the cells that build bone. As we age, increased osteoclastic activity can lead to osteopenia and osteoporosis, as there is more resorption than deposition of bone tissue. This process is affected by many lifestyle factors including diet, physical activity, tobacco and alcohol use and some medications.

Bone mass is also affected by race, family history, gender, menopausal status and body size. Hormones have a profound effect on bone mass: estrogen deficiency is the major contributing factor to bone loss after menopause and bone loss in men is highly associated with testosterone deficiency. Aromatase inhibitors, which prevent the conversion of testosterone into estradiol and are often used in treatment for prostate and breast cancer, have a significant impact on bone density. Excess cortisol production or use of glucocorticoids decreases bone density and increases fracture risk. Falling DHEA levels, thyroid disease, and parathyroid disorders all contribute to the acceleration of bone loss, and hormonal contraceptives have an impact through suppression of ovulation and lowered estradiol and progesterone levels. Additionally, a number of commonly used medications are linked to the acceleration of bone loss including:

  • Prednisone – oral and inhaled
  • Protein Pump Inhibitors/PPI’s: Protonix, Prevacid, Nexium, etc
  • Bisphosphonates – Fosamax, Boniva, Actonel, etc
  • SSRI’s – Zoloft, Lexapro, Sertraline, etc
  • Anti-psychotics – Risperadol, Haldol, Abilify, etc
  • Aromatase Inhibitors – Arimidex, Femara, etc
  • Anti-convulsants – Clonazepam, Diazepam, Lorazepam, etc
  • Heparin and Warfarin
  • Thiazolidinediones – Actos, Avandia, Rezulin, etc
  • Transplant Medications
  • GnRH agonists – for breast and prostate cancer
  • Excess thyroid hormone
  • DMPA (depo medroxyprogesterone acetate) – contraceptive

Bone contains both organic and inorganic components. The inorganic portion consists of bone mineral, and the organic portion is primarily Type I collagen. Collagen is linked together by molecules called pyridium cross-links. During bone resorption, these cross links, including one known as deoxypyridinoline (DPD) are broken down and excreted in urine where they can be measured and give valuable information about the rate of bone loss. When the rate of breakdown exceeds the rate of building, the result is a net loss of bone, and a decrease in bone mass (osteopenia, osteoporosis).

While measuring bone mineral density remains the gold standard for diagnosing osteoporosis and osteopenia, monitoring DPD levels offers valuable insight as to the rate of resorption which is a useful tool for monitoring treatment.

Hormone testing and DPD testing, both available at Labrix, are important for assessing bone health. For more information and to order test kits, call 877.656.9596 or visit the On Demand Webinar page at labrix.com to watch recorded educational videos on this and many other topics related to hormone, neurotransmitter and adrenal optimization.

References:
  • Arq Bras Endocrinol Metabol. 2014 Mar;58(2):162-71
  • JEndocrinol.2014;2014:496948. doi: 10.1155/2014/496948
  • Endocrinol Metab Clin North Am. 2012 Sep;41(3):595-611.


Labrix Core Training: Chicago

Dr. Lylen Ferris delivers a personal invitation for Labrix' upcoming Core Training in Chicago.




Labrix Clinical Spotlight Series:
Sexual Dysfunction in Women

Staff Physician Robyn Kutka discusses clinical approaches to identifying and treating sexual dysfunction in women as a part of our Labrix Clinical Spotlight Series



Labrix
Core Training
Chicago, IL
May 16, 2015

Labrix staff physicians will be in Chicago on May 16 to present Core Training. Registration is $150 and upon completing this one day training, you will receive a $100 credit on your testing account. Register for Labrix Core Training: Chicago today.


Labrix
Core Training
Portland, OR
August 1, 2015

Labrix staff physicians will be in Portland on August 1 to present Core Training. Registration is $150 and upon completing this one day training, you will receive a $100 credit on your testing account. Register for Labrix Core Training: Portland today.


SAVE THE DATE
Labrix Advanced
Workshop
Las Vegas, NV
January 16-17, 2016

CDID
Ft. Lauderdale, FL
April 23-26, 2015

Labrix' co-founder Dr. Lommen will be speaking at the ACA Council on Diagnosis and Internal Disorders conference in Ft. Lauderdale, FL. on April 24, 2015. Dr. Erin Lommen, ND will be speaking about "Menopause and Missing More than Periods"


IWHIM
Portland, OR
April 25-26, 2015

Dr. Erin Lommen will be also be speaking at the Institute of Women's Health & Integrative Medicine conference in Portland, OR. on April 25 & 26, 2015. Labrix will exhibit at the conference April 24 and 26.


AAMA
St. Louis, MO
April 23-26, 2015

Come visit our booth at the American Academy of Medical Acupuncture in St. Louis, MO. April 23-26, 2015.


A4M
Hollywood, FL
May 7-9, 2015

Labrix will also be exhibiting at A4M in Hollywood, FL. May 7-9 2015.